Date: Tuesday, October 23, 2018
Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment
Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
The humoral response to vaccination may be affected by the use of immunosuppressive drugs. The effect of secukinumab on the humoral response of vaccines is unknown.We aimed to assess the immunogenicity and safety of vaccination against seasonal influenza in psoriatic arthritis (PsA) patients treated with secukinumab in comparison with healthy controls
Patients with PsA fulfilling the CASPAR criteria treated with secukinumab for at least 3 months and healthy controls were vaccinated with the Sanofi Pasteur vaccine recommended by the WHO in 2017 composed of 3 antigens (H3N3, H1N1 and B/Victoria). Clinical and laboratory assessments were performed on the day of the vaccination and 4-6 weeks later. The immunogenicity of the vaccine was evaluated by haemagglutination inhibition assay against the 3 antigens included in the vaccine. Responders to each antigen were defined as patients who had a 4- fold increase in the titer of the antigen or if they seroconverted in cases where the baseline level was below 1/40.
The study included 32 consecutive PsA patients treated with secukinumab for more than 3 months with a median age of 52 years, 18(56%) females, 10 (31%) treated with concomitant conventional synthetic DMARDs, mostly methotrexate and 17 age/gender matched healthy controls (median age=48.5, females=6 (35%), males=11 (65%)). A significant increase in the geometric mean titers of each antigen was observed in both groups. The number of responders in each group was similar for H3N2, H1N1 and significantly higher in the PsA group for B /Victoria. The proportion of patients with a seroprotective level defined as a titer above1/40 was high and similar in both groups. No correlation was found between the rate of response and factors such as age, gender and parameters of disease activity. No increase was found in the different parameters of disease activity which included tender and swollen joint counts, Leeds enthesitis index, physician and patient global assessment, PASI and CRP.
Treatment with secukinumab does not affect the humoral response to influenza vaccine in patients with PsA.
To cite this abstract in AMA style:Elkayam O, Zisman D, Kaufman I, Arad U, Berman M, Furer V, Lahat Y, Carmi O, Haddad A, Elias M, Paran D, Mandelbaum M. The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-effect-of-secukinumab-on-the-immunogenicity-of-influenza-vaccine-in-patients-with-psoriatic-arthritis/. Accessed March 21, 2023.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-secukinumab-on-the-immunogenicity-of-influenza-vaccine-in-patients-with-psoriatic-arthritis/